(CercleFinance.com) – Oddo BHF maintains its ‘outperformance’ recommendation and its price target of 108 euros on Sanofi, after the FDA’s approval of Pfizer’s JAK1 inhibitor named Cibinqo, in the treatment of atopic dermatitis.
‘We initially considered the safety profile of the drug as a barrier to its market penetration compared to Sanofi’s Dupixent… the specific indication issued by the FDA proves us right,’ explains the analyst.
“The next few weeks will be oriented around the group’s clinic”, he continues, awaiting three phase III results during this first quarter, namely the vaccine against Covid-19, amcenestrant in breast cancer and efanesoctocog alfa in haemophilia A.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
